Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

SOUTH SAN FRANCISCO, Calif. and SHANGHAI: SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...

Click to view original post